Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) Sees Large Decline in Short Interest

Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) saw a significant drop in short interest during the month of July. As of July 31st, there was short interest totalling 91,800 shares, a drop of 8.0% from the June 30th total of 99,800 shares. Currently, 1.0% of the shares of the company are sold short. Based on an average daily volume of 78,500 shares, the days-to-cover ratio is presently 1.2 days.

Separately, ValuEngine downgraded Invivo Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st.

Shares of NASDAQ:NVIV remained flat at $$0.60 during midday trading on Thursday. The stock had a trading volume of 20,700 shares, compared to its average volume of 67,474. The firm has a market capitalization of $5.70 million, a PE ratio of -0.27 and a beta of 1.43. The stock’s fifty day moving average is $0.67 and its 200 day moving average is $1.16. Invivo Therapeutics has a 12 month low of $0.52 and a 12 month high of $2.75. The company has a quick ratio of 6.86, a current ratio of 6.86 and a debt-to-equity ratio of 0.09.

Invivo Therapeutics (NASDAQ:NVIV) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.03). Analysts forecast that Invivo Therapeutics will post -1.13 EPS for the current fiscal year.

About Invivo Therapeutics

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord.

Further Reading: What is cost of equity?

Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with's FREE daily email newsletter.